Investigating new treatments for ovarian cancer
Dana Farber/Harvard Cancer Center Ovarian Cancer SPORE grant
This study is looking for better ways to treat ovarian cancer, especially a type called high-grade serous ovarian cancer, by testing new drug combinations and a vaccine to help improve outcomes for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10895312 on NIH RePORTER |
What this research studies
This research focuses on improving therapies for ovarian cancer, particularly high-grade serous ovarian cancer. It includes clinical trials that explore the use of PARP inhibitors in combination with other drugs, as well as the development of a novel vaccine for patients. The research also aims to address challenges faced by patients with specific cancer mutations by testing new drug combinations and identifying biomarkers that predict treatment responses. Overall, the project seeks to enhance treatment options and outcomes for ovarian cancer patients.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients diagnosed with high-grade serous ovarian cancer, particularly those who have not responded to standard treatments.
Not a fit: Patients with non-ovarian cancers or those who have already exhausted all treatment options may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options and improved survival rates for ovarian cancer patients.
How similar studies have performed: Previous research has shown promise in using PARP inhibitors and immunotherapy for ovarian cancer, indicating that this approach could build on existing successes.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: D'andrea, Alan D. — Dana-Farber Cancer Inst
- Study coordinator: D'andrea, Alan D.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.